Aevi expands drug development deal with Japanese biopharm firm

Aevi Genomic Medicine said Wednesday it has expanded its collaboration with a Japanese biopharmaceutical company. Under the expanded partnership, Aevi of Wayne, Pa., signed an an option agreement for Kyowa Hakko Kirin Co. Ltd.'s early stage monoclonal antibody program in an ultra-orphan pediatric indication. Both the rare disease being targeted and the financial terms of the expanded deal are being kept conf idential. Aevi (NASDAQ:GNMX), formerly known as Medgenics, and Kyowa Hakko Kirin of Japan…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news